HDM1005 vs NNC0519-0130

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline

HDM1005

Developed by Hangzhou Zhongmei Huadong Pharmaceutical

Phase 3 in Obesitypeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07502001 (registry estimate)

No aligned efficacy figure on record for this race.

NNC0519-0130

Developed by Novo Nordisk

Phase 2 in Obesitypeptide
Partial signal

NCT06326060 · Phase 2 · completed

The study was randomized and quadruple-blind, included placebo and active-comparator arms, and enrolled 354 participants; its primary endpoint was the clinical measure of relative body-weight change. Because the registry does not report whether this endpoint was met, the findings cannot currently support the highest evidence grade.

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHDM1005NNC0519-0130
Body weight, % change—Trial running · NCT07279194—Not reported
Weight loss of 5% or more—Trial running · NCT07279194—Not reported
Weight loss of 10% or more—Trial running · NCT07279194—Not reported
Waist circumference, change (cm)—Trial running · NCT07279194—Not reported

Body weight, % change

HDM1005
—Trial running · NCT07279194
NNC0519-0130
—Not reported

Weight loss of 5% or more

HDM1005
—Trial running · NCT07279194
NNC0519-0130
—Not reported

Weight loss of 10% or more

HDM1005
—Trial running · NCT07279194
NNC0519-0130
—Not reported

Waist circumference, change (cm)

HDM1005
—Trial running · NCT07279194
NNC0519-0130
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HDM1005: no structured comparison results are available for Obesity.

NNC0519-0130: no structured comparison results are available for Obesity.

Type 2 Diabetes

Shared mechanism: GLP-1/GIP receptor (dual) · full Type 2 Diabetes pipeline

HDM1005

Developed by Hangzhou Zhongmei Huadong Pharmaceutical

Phase 3 in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2027 · NCT07394114 (registry estimate)

No aligned efficacy figure on record for this race.

NNC0519-0130

Developed by Novo Nordisk

Phase 2 in Type 2 Diabetespeptide
Weak signal

NCT05363774 · Phase 1 · completed

This was a randomized, blinded, placebo-controlled study, a genuine controlled design, but it measured only safety and drug levels rather than a clinical efficacy outcome, and results have not been posted yet, so the evidence reflects the design only. Its registered primary outcome on ClinicalTrials.gov is "Number of treatment emergent adverse events (TEAE) in single ascending dose (SAD) part" (with 3 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHDM1005NNC0519-0130
HbA1c, change—Trial running · NCT07394114—Not reported
Body weight, change (kg)—Trial running · NCT07394114—Not reported
HbA1c below 7%—Trial running · NCT07394114—Not reported
Fasting plasma glucose, change—Trial running · NCT07394114—Not reported
3-point MACE (% with event)—Trial running · NCT07394114—Not reported

HbA1c, change

HDM1005
—Trial running · NCT07394114
NNC0519-0130
—Not reported

Body weight, change (kg)

HDM1005
—Trial running · NCT07394114
NNC0519-0130
—Not reported

HbA1c below 7%

HDM1005
—Trial running · NCT07394114
NNC0519-0130
—Not reported

Fasting plasma glucose, change

HDM1005
—Trial running · NCT07394114
NNC0519-0130
—Not reported

3-point MACE (% with event)

HDM1005
—Trial running · NCT07394114
NNC0519-0130
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HDM1005: no structured comparison results are available for Type 2 Diabetes.

NNC0519-0130: no structured comparison results are available for Type 2 Diabetes.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HDM1005's landscape · NNC0519-0130's landscape